Avidity biosciences reports first quarter 2024 financial results and recent highlights

Initiation of global phase 3 harbor™ trial for del-desiran (aoc 1001) in dm1 on track for this quarter avidity to report  fshd data from fortitude™ trial this quarter and dmd data from explore44™ trial in 2h24 presented positive long-term del-desiran data from marina-ole™ showing reversal of disease progression in people living with myotonic dystrophy type 1 across multiple endpoints; same key endpoints, with vhot as primary, agreed for phase 3 harbor trial cash position of $915 million at the end of q124 following successful private placement san diego , may 9, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today reported financial results for the first quarter ended march 31, 2024, and highlighted recent corporate progress. "as we move forward with the planned initiation of our global phase 3 harbor™ study for del-desiran this quarter, we continue to work diligently to improve people's lives by advancing our aoc platform," said sarah boyce, president and chief executive officer at avidity.
RNA Ratings Summary
RNA Quant Ranking